Teva Divesting $1B in Assets to Clear Anti-Trust Hurdles for Allergan Deal

Source: Reuters

Dec 03, 2015

Teva Pharmaceutical Industries is divesting about $1 billion worth of assets to address antitrust concerns over its deal to buy Allergan's generic drug business, sources told Reuters.

Teva announced in July that it had signed a definitive agreement with Allergan to acquire Allergan Generics in a $40.5 billion transation.

Teva's divestiture will help keep the Allergan deal on schedule to close by the first quarter of 2016. It will also clear the way for the $160 billion Allergan Pfizer mega-merger, which is contingent on Allegan completing its generic drug sale to Teva.

The Teva assets being divested span the U.S., Europe and the Middle East, and will be sold in a series of processes, Reuters' sources reported.

Read the Reuter's article

Make sure you didn't miss anything: view our monthly news recap


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments